MedTrace Logo

CLEAR Sepsis Clinical Study

NCT03231956 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2020-03-18

No results posted yet for this study

Summary

To investigate the relationship between initial ClearSight™ derived hemodynamic parameters and outcomes (death, ongoing organ dysfunction or delayed ICU admission) in patients with acute infection and possible sepsis, with a focus on venous blood lactate (\< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dL) and hemodynamic subgroups, using ED patients presenting with minor infections or asthma/COPD exacerbations as controls (henceforth referred to as Sepsis Mimic Group).

Conditions

Interventions

DEVICE

ClearSight™ / EV1000NI Clinical Platform

Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System

Sponsors & Collaborators

  • Edwards Lifesciences

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-29
Primary Completion
2021-12-31
Completion
2022-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03231956 on ClinicalTrials.gov